Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 14:35:10693.
doi: 10.3389/ti.2022.10693. eCollection 2022.

Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice

Marina Lopez-Martinez  1   2 , Irina Torres  1   2 , Sheila Bermejo  1   2 , Francesc Moreso  1   2 , Clara Garcia-Carro  3   4 , Ander Vergara  1   2 , Natalia Ramos  1   2 , Manel Perello  1   2 , Alejandra Gabaldon  2   5 , M Antonieta Azancot  1   2 , Monica Bolufer  1   2 , Nestor Toapanta  1   2 , Oriol Bestard  1   2 , Irene Agraz-Pamplona  1   2 , Maria Jose Soler  1   2
Affiliations

Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice

Marina Lopez-Martinez et al. Transpl Int. .

Erratum in

No abstract available

Keywords: CKD progression; IgA nephropathy; IgAN recurrence in transplant kidney; TRF-budesonide; proteinuria reduction.

PubMed Disclaimer

Conflict of interest statement

ML‐M received support for attending meetings and/or travel from Sanofi and AstraZeneca. SB received consulting fees and payment for lectures, presentations, speakers, bureaus, manuscript writing or educational events, participation on a data safety monitoring board or advisory board from AstraZeneca and Mundipharma. CG‐C has received travel and congress fees support from AstraZeneca, Esteve, Novo Nordisk, Boehringer Ingelheim Lilly, Astellas, Otsuka, Novartis and Baxter, and has given scientific lectures and participated in advisory boards organized by AstraZeneca, Boehringer Ingelheim Lilly, Mundipharma and Novo Nordisk. AV received grants or contracts from Instituto Carlos III (ISCIII) and Fundación Alfonso Martín Escudero, support for attending meetings and/or travel from Mundipharma, Sanofi, and Novo Nordisk. NR Received grants from the participation on a data safety monitoring board or advisory board from Alexion. MS received grants or contracts from Boehringer, ISCIII, and Marató TV3; honoraria for lectures from NovoNordisk, Jansen, Boehringer, Mundipharma, AstraZeneca, Ingelheim Lilly, Vifor, ICU Medical, Fresenius, and Travere Therapeutics; support for attending meetings from Travere; participation on a data safety, monitoring board or advisory board from NovoNordisk, Jansen, Boehringer, Mundipharma, AstraZeneca, Ingelheim Lilly, Vifor, ICU Medical, Bayer, GE Healthcare, and Travere Therapeutics. MS has the following leadership or fiduaciary roles: SEC Board member, SEN board member, Ex ERA board member, Ex‐ASN Board News, Ex‐ERA‐EDTA SAB, Ex‐Council member ERA, Elected EIC CKJ. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. McGrogan A, Franssen CF, de Vries CS. The Incidence of Primary Glomerulonephritis Worldwide: a Systematic Review of the Literature. Nephrol Dial Transpl (2011) 26(2):414–30. 10.1093/ndt/gfq665 - DOI - PubMed
    1. Smerud HK, Bárány P, Lindström K, Fernström A, Sandell A, Pahlsson P, et al. New Treatment for IgA Nephropathy: Enteric Budesonide Targeted to the Ileocecal Region Ameliorates Proteinuria. Nephrol Dial Transpl (2011) 26:3237–42. 10.1093/ndt/gfr052 - DOI - PubMed
    1. Ismail G, Obrisca B, Jurubita R, Andronesi A, Sorohan B, Vornicu A, et al. Budesonide versus Systemic Corticosteroids in IgA Nephropathy. A Retrospective, Propensity-Matched Comparison. Medicine (2020) 99(26):e21000. 10.1097/MD.0000000000021000 - DOI - PMC - PubMed
    1. Lingaraj U, Aralapuram K, Chikkanayakanhalli S, Vishwanathan A, Vankalkunti M. Successful Treatment of a Patient with Posttransplant IgA Nephropathy with Targeted Release Formulation of Budesonide. Saudi J Kidney Dis Transpl (2020) 31(2):521–3. 10.4103/1319-2442.284029 - DOI - PubMed
    1. Fellström BC, Barratt J, Cook H, Coppo R, Feehaly J, de Fitjter JW, et al. Targeted-release Budesonide versus Placebo in Patients with IgA Nephropathy (NEFIGAN): a Double-Blind, Randomised, Placebo-Controlled Phase 2b Trial. Lancet (2017) 389(10084):2117–27. 10.1016/S0140-6736(17)30550-0 - DOI - PubMed